Zelluna ASA's Third Quarter 2025 Business Update
Zelluna (OSE: ZLNA) is at the forefront of developing innovative "off-the-shelf" T-cell receptor-based natural killer (TCR-NK) therapies targeting cancer treatment. This update outlines their significant achievements and financial results for the third quarter of 2025.
Key Highlights from Q3 2025
Regulatory Progress and Clinical Strategy
In October 2025, after the reporting period, Zelluna received positive feedback from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. This was an encouraging sign, showcasing their alignment with essential strategies across preclinical, manufacturing, clinical, and regulatory processes. The company plans to proceed with a Clinical Trial Application (CTA) for their ZI-MA4-1 therapy, gathering patient data expected mid-2026.
Advancements in First-in-Human Trials
Zelluna has been making strides in preparing for their first-in-human trial of ZI-MA4-1. Collaborating with respected cancer centers in the UK, they appointed Professor Fiona Thistlethwaite from The Christie in Manchester as the Chief Investigator. The Christie will lead the trial in partnership with Dr. Andrew Furness at The Royal Marsden Hospital in London. Both are eminent figures in oncology and early-phase cell therapies, having developed a solid trial design and strategy.
Clinical Material Manufacturing Initiated
The journey toward clinical readiness has gained momentum with the initiation of GMP (Good Manufacturing Practice) manufacturing. In July 2025, Zelluna started producing clinical batches for their planned Phase I trial. This key milestone builds upon the procedural groundwork laid earlier in the year and illustrates their commitment to delivering effective cell therapies.
Strategic Acquisition for Pipeline Expansion
During Q3, Zelluna made a strategic move by acquiring a portfolio of TCRs that target KKLC1 from a well-established biotechnology company. This acquisition strengthens Zelluna's TCR-NK pipeline by incorporating KKLC1, a clinically validated cancer antigen that synergizes with MAGE-A4. This development opens up avenues to broaden their reach to diverse patient populations.
Financial Performance Overview
In terms of financial performance, Zelluna reported the following for Q3 2025:
- Total operating expenses were MNOK 39.7, accumulating to MNOK 101.0 year-to-date.
- Total loss for the quarter amounted to MNOK 39.3, with a total loss of MNOK 98.7 year-to-date.
- Net negative cash flow from operations was MNOK 29.0 for Q3, leading to a net decrease in cash and cash equivalents of MNOK 28.9.
- On 30 September 2025, cash and cash equivalents totaled MNOK 47.2. The company anticipates this to sustain its operations through Q2 2026.
The quarterly report and additional information will be made available on Zelluna's website, and a webcast event for Q3 results will occur on the same day as this release. Attendees can participate by submitting questions during the session, which will also be archived for later access.
About Zelluna ASA
Zelluna ASA aspires to revolutionize cancer treatment by delivering therapies that have the potential to cure advanced solid tumors safely around the globe. Their innovative approach harnesses the immune system's capabilities through TCR-NK cell therapies, intended to be made available as "off-the-shelf" solutions to address the limitations of current therapies. The flagship product targets MAGE-A4, with plans for an expansive pipeline designed to benefit patients with various cancers.
Frequently Asked Questions
What significant feedback did Zelluna receive from the MHRA?
Zelluna received positive feedback from the MHRA, aligning their clinical and regulatory strategies for the upcoming ZI-MA4-1 therapy.
Who will lead Zelluna's first-in-human trial?
Professor Fiona Thistlethwaite from The Christie in Manchester has been appointed as the Chief Investigator for the trial.
What is the current cash position of Zelluna ASA?
As of 30 September 2025, Zelluna reported cash and cash equivalents totaling MNOK 47.2, projected to last until Q2 2026.
What is the focus of Zelluna's TCR-NK therapies?
Zelluna's TCR-NK therapies focus on treating various solid cancers effectively and safely with a unique "off-the-shelf" approach.
How does Zelluna's pipeline position itself in the biotech industry?
Zelluna's pipeline, bolstered by a recent acquisition of TCRs, positions them favorably in the biotech industry with innovative cancer treatment solutions.
